Abstract
Priming of polymorphonuclear leukocytes (PMNs) enhances their adhesion to endothelium, the release of their granule content and their production of reactive oxygen species. These effects are etiological in transfusion related acute lung injury (TRALI) and many clinically important mediators of TRALI prime PMNs. A priming activity that develops over time in stored blood products has been shown to be due to the accumulation of lysophospatidylcholines (lyso-PCs) and has been found to be related clinically to TRALI. Lyso- PCs prime PMNs activating the G2A receptor and several inhibitors of this receptor, which could potentially be therapeutic in TRALI, have been identified. Recent work has described early steps in the signaling from the G2A receptor which has revealed potential targets for novel antagonists of lyso-PC mediated priming via G2A. Additionally, characterization of the process by which lyso-PCs are generated in stored blood products could allow development of inhibitors and additive solutions to block their formation in the first place.
Keywords: Transfusion-related acute lung injury, lysophospholipid, lysophosphatidylcholine, G2A receptor, G-protein coupled receptor, clathrin-mediated endocytosis, polymorphonuclear leukocytes (PMNs), blood products, inhibitors, additive solutions
Current Pharmaceutical Design
Title:Therapeutic Options for Transfusion Related Acute Lung Injury; the Potential of the G2A Receptor
Volume: 18 Issue: 22
Author(s): Michael A. Ellison, Daniel R. Ambruso and Christopher C. Silliman
Affiliation:
Keywords: Transfusion-related acute lung injury, lysophospholipid, lysophosphatidylcholine, G2A receptor, G-protein coupled receptor, clathrin-mediated endocytosis, polymorphonuclear leukocytes (PMNs), blood products, inhibitors, additive solutions
Abstract: Priming of polymorphonuclear leukocytes (PMNs) enhances their adhesion to endothelium, the release of their granule content and their production of reactive oxygen species. These effects are etiological in transfusion related acute lung injury (TRALI) and many clinically important mediators of TRALI prime PMNs. A priming activity that develops over time in stored blood products has been shown to be due to the accumulation of lysophospatidylcholines (lyso-PCs) and has been found to be related clinically to TRALI. Lyso- PCs prime PMNs activating the G2A receptor and several inhibitors of this receptor, which could potentially be therapeutic in TRALI, have been identified. Recent work has described early steps in the signaling from the G2A receptor which has revealed potential targets for novel antagonists of lyso-PC mediated priming via G2A. Additionally, characterization of the process by which lyso-PCs are generated in stored blood products could allow development of inhibitors and additive solutions to block their formation in the first place.
Export Options
About this article
Cite this article as:
A. Ellison Michael, R. Ambruso Daniel and C. Silliman Christopher, Therapeutic Options for Transfusion Related Acute Lung Injury; the Potential of the G2A Receptor, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023255
DOI https://dx.doi.org/10.2174/1381612811209023255 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Near Infrared Spectroscopy in Healthy Preterm and Term Newborns: Correlation with Gestational Age and Standard Monitoring Parameters
Current Neurovascular Research Renal Sympathetic Denervation and Renal Physiology
Current Clinical Pharmacology An Insight into the Therapeutic Potential of Major Coffee Components
Current Drug Metabolism Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Flaxseed and Endotoxic Shock
Current Pharmaceutical Design Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry A Discussion of Natural Rubber Latex Allergy with Special Reference to Children: Clinical Considerations
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Targeting <i>Plasmodium Metabolism</i> to Improve Antimalarial Drug Design
Current Protein & Peptide Science Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Meta-Analysis of Creatine for Neuroprotection Against Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Neurogenesis and Sensorimotor Gating: Bridging a Microphenotype and an Endophenotype
Current Molecular Medicine Perspectives on Therapeutic Target for Multiple System Atrophy
Recent Patents on Regenerative Medicine Statins as Antihypertensives
Recent Patents on Cardiovascular Drug Discovery Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Kounis Syndrome Following Beta-Lactam Antibiotic Use: Review of Literature
Inflammation & Allergy - Drug Targets (Discontinued) Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry